Media & Resources

The International AIDS Vaccine Initiative (IAVI) applauds the UNAIDS-Lancet Commission’s call for the world to urgently step up efforts to expand access to HIV/AIDS treatment and to “get serious” about prevention, including supporting development of an HIV vaccine. Without these stepped-up efforts, the world will “risk the epidemic rebounding” and “face more HIV infections and…

New research led by scientists at The Scripps Research Institute (TSRI), International AIDS Vaccine Initiative (IAVI) and The Rockefeller University shows that an experimental vaccine candidate can stimulate the immune system to block HIV infection in mice. The new candidate has the potential to inform immunization strategies against AIDS for humans. The effort to develop…

On the occasion of the visit of Dutch Prime Minister, Mr. Mark Rutte, to New Delhi, the two countries plan to expand their existing cooperation in the area of large scale patient cohorts with a Joint Cohort study on HIV patients in India. It is proposed that the joint cohort study will be executed by…

The International AIDS Vaccine Initiative (IAVI) congratulates its Board Chair, Dr. Alex Godwin Coutinho, on receiving an honorary doctorate degree from the University of Zurich’s (UZH) Medical Faculty. The degree recognizes the Ugandan medical doctor and global HIV/AIDS champion for his outstanding achievements in treatment and prevention. Coutinho is the former Executive Director of the…

NEW YORK – An IAVI-led team of scientists has defined an additional way to generate trimers from the major HIV subtypes A, B and C, with scalable properties that could benefit future clinical development of HIV vaccine candidates designed to elicit broadly neutralizing antibodies. The trimer is the critical target on the surface of HIV…

NEW YORK – Margaret McGlynn will step down after four years as President and CEO of the International AIDS Vaccine Initiative (IAVI). A search for her successor is underway, led by IAVI’s Board of Directors. “Margie’s outstanding experience as head of Merck global vaccines and her unique blend of professionalism and dedication have strongly positioned…

IAVI welcomes the promising results that Michael Farzan and his team have achieved by constructing an artificial protein that potently blocked HIV and SIV in vitro and protected against SHIV challenge in monkeys. These findings complement other ongoing studies aimed at designing prevention approaches that can work across the enormous diversity of HIV, and further…

New findings inform prevention, treatment and cure research and development.